Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
暂无分享,去创建一个
S. Steinberg | Y. Pommier | S. Bates | M. Aladjem | J. Doroshow | E. Szabo | U. Guha | J. Trepel | C. Redon | Min-Jung Lee | Yiping Zhang | J. Ji | Anish Thomas | Sunmin Lee | A. Rajan | R. Kinders | R. Hassan | W. Yutzy | E. Padiernos | Lan T. Tran | C. Alewine | A. Yuno | Haobin Chen | Linda Sciuto | Akira Yuno | Emerson B Padiernos
[1] M. Lawrence,et al. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. , 2017, Cancer research.
[2] M. Ellis,et al. CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.
[3] A. Nicolas,et al. The impact of replication stress on replication dynamics and DNA damage in vertebrate cells , 2017, Nature Reviews Genetics.
[4] K. Ishii,et al. DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity , 2017, The Journal of Immunology.
[5] S. Jackson,et al. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. , 2017, Cancer discovery.
[6] Samuel E. Jones,et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A , 2016, Nature Communications.
[7] Y. Pommier,et al. Small cell lung cancer: Time to revisit DNA-damaging chemotherapy , 2016, Science Translational Medicine.
[8] N. Tunariu,et al. Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. , 2016 .
[9] O. Fernandez-Capetillo,et al. A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors. , 2016, Molecular cell.
[10] T. Stankovic,et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. , 2016, Blood.
[11] N. Horita,et al. Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients , 2015, Scientific Reports.
[12] T. Stankovic,et al. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway , 2015, The Lancet.
[13] H. Wakimoto,et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors , 2015, Science.
[14] Y. Pommier,et al. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. , 2014, Cancer research.
[15] Abdelghani Mazouzi,et al. DNA replication stress: causes, resolution and disease. , 2014, Experimental cell research.
[16] P. Reaper,et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970 , 2014, Oncotarget.
[17] D. Cortez,et al. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. , 2014, Cancer research.
[18] K. Cimprich,et al. Causes and consequences of replication stress , 2013, Nature Cell Biology.
[19] C. Seedhouse,et al. Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells , 2013, PloS one.
[20] B. Cornelissen,et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation , 2012, Cell Death and Disease.
[21] W. Mckenna,et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition , 2012, British Journal of Cancer.
[22] O. Fernandez-Capetillo,et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. , 2012, The Journal of clinical investigation.
[23] M. Barbacid,et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.
[24] P. Reaper,et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.
[25] James R Bischoff,et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations , 2011, Nature Structural &Molecular Biology.
[26] A. Nakamura,et al. Recent developments in the use of γ -H2AX as a quantitative DNA double-strand break biomarker , 2011, Aging.
[27] B. Nabet,et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. , 2010, Cancer research.
[28] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[29] Y. Pommier. Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.
[30] A. Pettitt,et al. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes , 2004, Oncogene.
[31] Kai Rothkamm,et al. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] Junjie Chen,et al. Histone H2AX Is Phosphorylated in an ATR-dependent Manner in Response to Replicational Stress* , 2001, The Journal of Biological Chemistry.
[33] D. Lawrence,et al. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. , 2000, Journal of the National Cancer Institute.
[34] M. Ratain,et al. Topoisomerase I Inhibitors. , 1997, The oncologist.